Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
19(59%)
Results Posted
67%(4 trials)
Terminated
1(3%)

Phase Distribution

Ph phase_1
7
22%
Ph not_applicable
5
16%
Ph phase_2
12
38%
Ph phase_3
4
13%

Phase Distribution

7

Early Stage

12

Mid Stage

4

Late Stage

Phase Distribution28 total trials
Phase 1Safety & dosage
7(25.0%)
Phase 2Efficacy & side effects
12(42.9%)
Phase 3Large-scale testing
4(14.3%)
N/ANon-phased studies
5(17.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

19

trials recruiting

Total Trials

32

all time

Status Distribution
Active(22)
Completed(6)
Terminated(2)
Other(2)

Detailed Status

Recruiting15
Completed6
Active, not recruiting4
Not yet recruiting3
unknown2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
32
Active
19
Success Rate
85.7%
Most Advanced
Phase 3

Trials by Phase

Phase 17 (25.0%)
Phase 212 (42.9%)
Phase 34 (14.3%)
N/A5 (17.9%)

Trials by Status

unknown26%
completed619%
not_yet_recruiting39%
withdrawn13%
recruiting1547%
active_not_recruiting413%
terminated13%

Recent Activity

Clinical Trials (32)

Showing 20 of 32 trialsScroll for more
NCT07061977Phase 3

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

Recruiting
NCT05564390Phase 2

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Recruiting
NCT06169124Phase 2

Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

Active Not Recruiting
NCT04333537Phase 2

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

Recruiting
NCT06064097Phase 2

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

Recruiting
NCT07225985Phase 1

Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

Recruiting
NCT07539454Phase 2

Nirogacestat in Patients With Kaposi Sarcoma

Not Yet Recruiting
NCT06954987Phase 2

Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Not Yet Recruiting
NCT06871410Phase 1

Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
NCT01612481Phase 2

Phase II Study Evaluating Strategies of Lung Surveillance of Patients Operated of High Grade Soft Tissue Sarcoma

Terminated
NCT04751409Phase 2

Evaluating the Impact of Limited Compared With Intense Post-Operative Surveillance on Patient-Reported Outcomes in Patients With Stage II-III Soft Tissue Sarcoma of the Trunk and Extremities

Recruiting
NCT00352534Phase 3

Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor

Active Not Recruiting
NCT05497804Phase 2

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

Active Not Recruiting
NCT06593106Not Applicable

Cryodevitalization for the Treatment of Early Stage Lung Cancer, CRYSTAL Trial

Recruiting
NCT05806515Phase 2

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

Recruiting
NCT06470243Phase 3

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

Recruiting
NCT05641831Phase 2

Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study

Recruiting
NCT06042725Phase 1

MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma

Recruiting
NCT02068794Phase 1

MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Active Not Recruiting
NCT06928662Phase 1

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

Recruiting

Drug Details

Intervention Type
PROCEDURE
Total Trials
32